In a report released today, James Gordon from J.P. Morgan reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report). The company’s shares opened today at p2,154.00. See what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback